Analystreport

Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.

Cidara Therapeutics, Inc.  (CDTX) 
Last cidara therapeutics, inc. earnings: 3/4 05:55 am Check Earnings Report
US:NASDAQ Investor Relations: ir.cidara.com